Anti‐cytokine, all‐cause mortality ‐ uncertain risk of bias · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies probably leads to lower anti‐cytokines versus placebo, all‐cause mortality compared with placebo (moderate certainty).
3 findings from 1 review
RR 0.92 [0.86, 0.97]
9 studies · 7893 participants
Moderate
RR 0.91 [0.86, 0.97]
7 studies · 7752 participants
Moderate
RR 0.89 [0.8, 1]
4 studies · 2687 participants
Moderate
Anti‐endotoxin ‐ HA‐1A versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
It is very uncertain whether monoclonal antibodies changes anti‐endotoxin ‐ HA‐1A versus placebo, all‐cause mortality compared with placebo (very low certainty).
3 findings from 1 review
RR 0.8 [0.54, 1.2]
3 studies · 2668 participants
Very low
RR 1.01 [0.94, 1.09]
6 studies · 4443 participants
Moderate
RR 0.92 [0.79, 1.06]
8 studies · 4676 participants
Low
Anti‐endotoxins Anti‐LPS versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxins Anti‐LPS versus placebo, all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
Anticytokine ‐ anti‐TNF‐alpha versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies probably leads to lower anticytokine ‐ anti‐TNF‐alpha versus placebo, all‐cause mortality compared with placebo (moderate certainty).
1 finding from 1 review
Anti‐cytokines ‐ human interleukin‐1receptor antagonist versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐cytokines ‐ human interleukin‐1receptor antagonist versus… compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortalityb
It is very uncertain whether booster changes all‐cause mortalityb compared with placebo/no booster (very low certainty).
1 finding from 1 review
All‐cause mortalityf
mRNA‐1273 – ModernaTX showed no clear difference in all‐cause mortalityf compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortalityh
It is very uncertain whether CVnCoV – CureVac AG changes all‐cause mortalityh compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortalityf
ChAdOx1 – AstraZeneca + University of Oxford showed no clear difference in all‐cause mortalityf compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortalityg
BNT162b2 – Pfizer/BioNTech + Fosun Pharma showed no clear difference in all‐cause mortalityg compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortalityb
AD26.COV2.S – Janssen Pharmaceutical Companies leads to lower all‐cause mortalityb compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortalityf
It is very uncertain whether gam‐COVID‐VAC – Sputnik V changes all‐cause mortalityf compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortalityh
CoronaVac – Sinovac showed no clear difference in all‐cause mortalityh compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortalityÂ
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortalitye
BBV152 – Bharat Biotech showed no clear difference in all‐cause mortalitye compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortalityh
NVX‐CoV2373 – Novavax showed no clear difference in all‐cause mortalityh compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortalitye
FINLAY‐FR‐2 – Instituto Finlay de Vacunas probably leads to lower all‐cause mortalitye compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether sarilumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review
All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether clazakizumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review